CLINICAL EFFICACY AND COMPLICATION TRENDS OF TURP IN MANAGING BENIGN PROSTATIC HYPERPLASIA
European Journal of Clinical Pharmacy · 04.07.2025 · 7 (1) · 6969-6973
DOI: 10.61336/ejcp/25-08-440 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 04.07.2025.
Abstract (Originalsprache)
Transurethral resection of the prostate (TURP) remains the gold-standard surgical treatment for benign prostatic hyperplasia (BPH). However, outcomes from peripheral and resource-limited settings in Pakistan are less frequently reported, where patient profiles and perioperative resources may differ from tertiary centers.
Objective
To evaluate the clinical efficacy, perioperative outcomes, complication trends, and length of hospital stay among patients undergoing TURP.
Methods
This retrospective cohort study reviewed records of 127 men aged 45–85 years who underwent TURP between November 2023 and March 2024 at Timergara DHQ Hospital Dir Lower and RHQ Skardu. The Patients with prior prostate surgery, malignancy, bladder stones, or urethral strictures were excluded. Data included demographics, prostate volume, operative time, pre- and postoperative hemoglobin and sodium levels, postoperative complications, and hospital stay. Statistical analysis was performed using SPSS v21, with significance set at p ≤ 0.05.
Results
The mean age was 65.2 ± 10.3 years, and mean prostate volume was 66.8 ± 19.7 mL. A significant postoperative reduction in hemoglobin was observed (p < 0.01), while postoperative sodium changes were not significant (p = NS), indicating a low risk of TUR syndrome. Overall complication rates were low: blood transfusion 18%, sepsis 7%, TUR syndrome 1%, and bladder perforation 1%. The mean operative time was 125.6 ± 32.8 minutes, and the mean hospital stay was 4.1 ± 1.8 days.
Conclusion
Demonstrated favorable perioperative outcomes with low complication rates and short hospital stay, comparable to published results with other tertiary centers. Standardized perioperative care and early risk stratification may further improve outcomes in resource-limited settings.
Zitieren
APA
(2025). CLINICAL EFFICACY AND COMPLICATION TRENDS OF TURP IN MANAGING BENIGN PROSTATIC HYPERPLASIA. European Journal of Clinical Pharmacy, 7(1), 6969-6973. https://doi.org/10.61336/ejcp/25-08-440
Vancouver
CLINICAL EFFICACY AND COMPLICATION TRENDS OF TURP IN MANAGING BENIGN PROSTATIC HYPERPLASIA. European Journal of Clinical Pharmacy. 2025;7(1):6969-6973. doi:10.61336/ejcp/25-08-440
BibTeX
@article{euvimed2025,
title = {CLINICAL EFFICACY AND COMPLICATION TRENDS OF TURP IN MANAGING BENIGN PROSTATIC HYPERPLASIA},
journal = {European Journal of Clinical Pharmacy},
year = {2025},
volume = {7},
number = {1},
pages = {6969--6973},
doi = {10.61336/ejcp/25-08-440}
}
EUVIMED